Heavy document released, Chinese medicine enterprises "going out" and speeding up

[Pharmaceutical Network Industry News] A few days ago, the General Office of the State Council issued the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" (hereinafter referred to as the "Plan"), which clarified the guiding ideology, basic principles, and development of traditional Chinese medicine during the "14th Five-Year Plan" period.
Objectives, main tasks and priority measures
.

It is reported that this is the first five-year plan for traditional Chinese medicine issued in the name of the General Office of the State Council
.

Among them, it is worth mentioning that the "Planning" clearly proposes to expand the international trade of traditional Chinese medicine
.

Vigorously develop TCM service trade and build a high-quality national TCM service export base; promote the overseas localization of TCM, promote industrial collaboration and international trade; encourage the development of "Internet + TCM trade"; gradually improve the "going out" of TCM Relevant measures, carry out policy research on the overseas market of traditional Chinese medicine, and help traditional Chinese medicine enterprises to "go global"
.

According to the industry, the plan will help Chinese medicine enterprises to "go global" and speed up
.

It is understood that in fact, the country has been vigorously promoting the development of traditional Chinese medicine "going overseas" in recent years, and has successively issued the "Thirteenth Five-Year Plan for the Development of Traditional Chinese Medicine", "The "Belt and Road" Development Plan for Traditional Chinese Medicine (2016-2020), "About Opinions on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicine" and other documents to provide fundamental guidelines for promoting the high-quality development of traditional Chinese medicine and the industry
.

Driven by a series of documents, various localities have also begun to accelerate the international development of traditional Chinese medicine
.

As not long ago, Shandong Province issued the "Implementation Plan for the Construction of China (Shandong) Pilot Free Trade Zone Linkage and Innovation Zone" (hereinafter referred to as the "Plan"), which clearly uses the Shandong-Guangdong-Macao traditional Chinese medicine linkage innovation mechanism to promote the "borrowing of traditional Chinese medicine from Macao".
"Going overseas" international development
.

The "Plan" proposes to promote the inheritance and innovation of traditional Chinese medicine
.

Give full play to the advantages of traditional Chinese medicine industry agglomeration in Jinan area, link Jining High-tech Industrial Development Zone and Dong'e Economic Development Zone, and strengthen cooperation in the fields of Chinese patent medicine preparations, Chinese herbal decoction pieces, and Chinese herbal medicine planting
.

Relying on the national cultural export base in Jinan area, we will help traditional Chinese medicine cultural products and "China Time-honored Brands" enterprises to "go global", further expand overseas sales channels, and realize overseas publicity and promotion of traditional Chinese medicine culture and products
.

 　　Thanks to policy support, more and more Chinese medicine companies have begun to accelerate their development and expand their overseas business
.

It is understood that seven Chinese patent medicine products, Liuwei Dihuang Pill, Qiju Dihuang Pill, Guipi Pill, Xiaoyao Pill, Zhibai Dihuang Pill, Buzhong Yiqi Pill and Guifu Dihuang Pill produced by Jiuzhitang have obtained the Brazilian National Health Supervision.
The company has already opened up the Brazilian market and hopes to further develop overseas markets with the help of government resources, and send more high-quality Chinese medicine products of the company abroad
.

 　　In addition, Yiling Pharmaceutical's Lianhua Qingwen capsules have sold more than 400 million boxes worldwide
.

As of July 2021, its Lianhua Qingwen capsules have also obtained registration approvals or import licenses in 24 countries and regions, including Canada, Russia, Brazil,
etc.

 　　In general, in the international pharmaceutical market, many Chinese pharmaceutical companies were at the bottom of the value chain in the past, and their profits were very meager
.

But over the years, the phenomenon is undergoing a fundamental reversal
.

With the continuous favorable policies, the R&D, production, and manufacturing capabilities of Chinese pharmaceutical companies, including the ability to integrate resources around the world, have not been what they used to be
.

Although there are still many challenges, the industry generally believes that the international development space of traditional Chinese medicine will become wider and wider
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.